Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma.

Abstract

Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. Materials & methods: US-based community oncologists identified patients with RRMM treated with or without pomalidomide following first-line lenalidomide. Disease response (≥ very good partial response) and progression-free survival were compared. Results: Disease response was 78.6 and 51.7% for pomalidomide (n = 126) and nonpomalidomide cohorts (n = 174), respectively (p < 0.0001). Multivariate adjusted odds of response were 4.5-times greater for pomalidomide cohort (p < 0.0001). Median progression-free survival was not reached for pomalidomide cohort and 16.7 months for nonpomalidomide cohort (log-rank p < 0.01). Conclusion: Following lenalidomide induction in RRMM, pomalidomide is an effective treatment.

• Authors: Tomer Mark, Angelica Falkenstein, Jonathan Kish
• Journal: Future oncology (London, England) (Future Oncol) Vol. 18 Issue 5 Pg. 553-564 (Feb 2022) ISSN: 1744-8301 [Electronic] England
• PMID: 34787472 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Angiogenesis Inhibitors
• Thalidomide
• pomalidomide
• Lenalidomide

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Female
• Humans
• Lenalidomide (therapeutic use)
• Male
• Middle Aged
• Multiple Myeloma (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)
• Progression-Free Survival
• Retrospective Studies
• Thalidomide (analogs & derivatives, therapeutic use)